NHS England, the Association of the British Pharmaceutical Industry (ABPI) and the AHSN Network have joined forces to launch an ambitious new programme, connecting digital health innovators with pharmaceutical companies to explore new innovations that could help people living with diabetes.
The Diabetes Hothouse is the first initiative arising from the NHS England and ABPI Priority Delivery Agreement launched earlier this year, which seeks to facilitate faster access of new, evidenced based technology for patients.
The Diabetes Hothouse is calling for innovators with market-ready, digital or digitally-enabled innovations to take part in the programme. Successful innovations, with evidence of strong impact of improving outcomes for people with diabetes will receive support in either funding or clinical expertise so they can spread their solutions across the country.
The digital innovations might be either novel uses of existing technologies or new innovations, and could include software, apps, hybrid technology-service and device-software that support pathway improvement, better diagnosis, or improved management in line with the tailored needs of the patient.
Five pharmaceutical companies are participating in the Diabetes Hothouse and will progress the selected collaboration projects in partnership with NHS England.
Applications are welcomed from companies of all sizes, individuals, NHS teams and charities who are interested in forming collaborations to test the ability of digital solutions to address the triple aims of improving safety, efficiency and patient outcomes.
The innovations must also support existing national diabetes priorities so that patients receive the right care at the right time. These are:
The closing date for applications is 5 November 2018.
For more information and application forms visit the AHSN Network website.